Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up

• Published in: Journal of cancer research and therapeutics 2023-01, Vol.19 (2), p.183-190
• Main Authors: Jimenez-Gomez, Marta, Loro-Pérez, Jorge, Vega-Benítez, Victor, Hernández-Hernández, Juan Ramon, Aguirre, Nuria Argudo
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Axilla; Axillary dissection; Biopsy; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - radiotherapy; Cancer; Cancer patients; Care and treatment; Chemotherapy; Diagnosis; Dissection; Female; Follow-Up Studies; Hospitals, University; Humans; Lymphatic system; Metastasis; Methods; Methylene blue; Oncology, Experimental; Pertuzumab; Prevention; Prognosis; Radiation therapy; Radiotherapy; Sentinel Lymph Node Biopsy; Tumor staging
• ISSN: 0973-1482; 1998-4138; 1998-4138
• DOI: 10.4103/jcrt.jcrt_263_22

Axillary lymph node dissection (ALND) was the standard in breast cancer with axillary involvement until recently. Along with the number of metastatic nodes, axillary positivity was considered a main prognostic factor and scientific evidence shows that the administration of radiotherapy on ganglion areas decreases the risk of recurrence even in positive axilla. The objective of this study was to evaluate the axillary treatment in patients with positive axilla at diagnosis, the evolution of them over time, and to assess patient's follow-up with the aim of avoiding the morbidity associated with axillary dissection. A retrospective observational study of breast cancer patients diagnosed between 2010 and 2017 was performed. In total, 1,100 patients were studied, out of which 168 were women with clinically and histologically positive axilla at diagnosis. Seventy-six percent received primary chemotherapy and subsequent treatment with sentinel node biopsy, axillary dissection, or both. Patients with positive sentinel lymph node biopsy received either radiotherapy or lymphadenectomy depending on the year time they were diagnosed. For 60 patients out of 168, neoadjuvant chemotherapy resulted in a complete pathological axillary response. Axillary recurrence was registered for six patients. No recurrence was detected in the biopsy group associated with radiotherapy. These results support the benefit of lymph node radiotherapy for patients with positive sentinel node biopsy after receiving primary chemotherapy. Sentinel node biopsy provides useful and reliable information about cancer staging and might prevent lymphadenectomy, leading to a decrease in morbidity. Pathological response to systemic treatment came out as the most important predictive factor of disease-free survival of breast cancer.